Ozempic and Wegovy Might Be Supercharging Your Taste Buds

Semaglutide, the active ingredient in well-known diabetes and obesity drugs Ozempic and Wegovy, can also tweak people’s taste buds for the superior, preliminary analysis suggests. Scientists discovered that females taking semaglutide enhanced their taste sensitivity, specifically to sweetness. The findings may well illuminate a different cause why it and related drugs can so successfully enable men and women drop weight, the authors say.

The analysis was led by scientists from the University Health-related Center in Ljubljana, Slovenia. They have been intrigued by animal research that appeared to show GLP-1, a hormone crucial to the body’s manage of blood sugar and hunger, also plays an crucial function in influencing the perception of sweetness. In mice bred to no longer create GLP-1, for instance, their sensitivity to sweetness appears significantly lowered.

Semaglutide and other incretins are created to mimic GLP-1, and some analysis has discovered that men and women on the drug have a tendency to knowledge a decline in need for sweet, savory and salty foods. The mechanisms behind this shift are not totally clear, having said that, so the researchers wanted to see if a related modify in taste sensitivity can occur in humans as effectively as mice taking semaglutide.

It may well sound unintuitive, but growing taste sensitivity could basically enable with weight loss by minimizing the need for excessively sweet, higher-calorie foods. By perceiving sweetness a lot more intensely, men and women may well really feel happy with smaller sized amounts of sugar, top to a reduce in general calorie intake.

The group carried out a 16-week-extended trial with 30 females volunteers, with half getting the drug and the other half a placebo. The volunteers had their taste sensitivity measured working with strips containing all 4 simple tastes (sweet, salty, sour, and bitter) placed on their tongue. In addition, some of their tongue cells have been collected to examine gene expression, and they underwent an MRI scan prior to and soon after tasting a thing sweet following a common meal.

“The present study demonstrated that semaglutide enhanced taste sensitivity in females with obesity, which means that the detection threshold for various concentrations of 4 simple tastes have been enhanced,” lead study author Mojca Jensterle Sever told Gizmodo.

The group also discovered that the tongue cells of these taking semaglutide skilled alterations in the expression of genes linked to the perception of sweetness and the renewal of taste buds. And by means of the MRI scans, they discovered alterations in how users’ brains responded to sweetness, specifically in the angular gyrus of the parietal cortex. The angular gyrus is believed to enable integrate our various senses to superior have an understanding of the globe about us and resolve complications, when the parietal cortex is recognized to have cells that carry GLP-1 receptors.

The team’s findings are getting presented this weekend at ENDO 2024, so they haven’t however undergone the standard peer-overview method. Sever notes their analysis is only a proof-of-notion study, intended to show that there’s a thing a lot more to discover, not to definitively confirm a phenomenon. Given that taste perception can differ substantially involving various men and women, it is also doable that GLP-1 drugs would not have an effect on everyone’s taste buds the identical way.

But analysis has recommended that at least some men and women with obesity perceive sweetness significantly less intensely than usual, which may well then enable drive their craving for even sweeter, typically a lot more calorie-filled foods. GLP-1 drugs are believed to enable treat obesity in many techniques, such as by prompting the sense of fullness earlier into a meal than prior to. And it is definitely doable that enhancing people’s sensitivity to sweetness may well be a different, the authors say.

“Our study delivers ‘food for thought’ on the further mechanisms by which semaglutide and other incretin-primarily based therapies facilitate alterations in meals preference and consuming behavior that may well potentially lead to reductions in physique weight beyond appetite suppression and enhanced manage of consuming,” Sever stated.

Future research, hopefully addressing the limitations of this present analysis, “will clarify irrespective of whether the efficacy of semaglutide in treating obesity is also a matter of taste,” she added.